JP2005505605A5 - - Google Patents

Download PDF

Info

Publication number
JP2005505605A5
JP2005505605A5 JP2003535798A JP2003535798A JP2005505605A5 JP 2005505605 A5 JP2005505605 A5 JP 2005505605A5 JP 2003535798 A JP2003535798 A JP 2003535798A JP 2003535798 A JP2003535798 A JP 2003535798A JP 2005505605 A5 JP2005505605 A5 JP 2005505605A5
Authority
JP
Japan
Prior art keywords
rosuvastatin
medicament
patient
risk
dementia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003535798A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005505605A (ja
Filing date
Publication date
Priority claimed from SE0103509A external-priority patent/SE0103509D0/xx
Application filed filed Critical
Publication of JP2005505605A publication Critical patent/JP2005505605A/ja
Publication of JP2005505605A5 publication Critical patent/JP2005505605A5/ja
Pending legal-status Critical Current

Links

JP2003535798A 2001-10-19 2002-10-18 前痴呆状態におけるロスバスタチン Pending JP2005505605A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0103509A SE0103509D0 (sv) 2001-10-19 2001-10-19 Rosuvastatin in pre demented states
PCT/SE2002/001911 WO2003032995A1 (en) 2001-10-19 2002-10-18 Rosuvastatin in pre demented states

Publications (2)

Publication Number Publication Date
JP2005505605A JP2005505605A (ja) 2005-02-24
JP2005505605A5 true JP2005505605A5 (https=) 2006-01-05

Family

ID=20285721

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003535798A Pending JP2005505605A (ja) 2001-10-19 2002-10-18 前痴呆状態におけるロスバスタチン

Country Status (19)

Country Link
US (1) US20060229321A1 (https=)
EP (1) EP1446123A1 (https=)
JP (1) JP2005505605A (https=)
KR (1) KR20040058201A (https=)
CN (1) CN1604780A (https=)
AR (1) AR036891A1 (https=)
BR (1) BR0213434A (https=)
CA (1) CA2463597A1 (https=)
CO (1) CO5580773A2 (https=)
HU (1) HUP0401798A3 (https=)
IL (1) IL161380A0 (https=)
IS (1) IS7218A (https=)
MX (1) MXPA04003631A (https=)
NO (1) NO20041840L (https=)
PL (1) PL369573A1 (https=)
RU (1) RU2004112422A (https=)
SE (1) SE0103509D0 (https=)
WO (1) WO2003032995A1 (https=)
ZA (1) ZA200402844B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005023778A2 (en) 2003-08-28 2005-03-17 Teva Pharmaceutical Industries Ltd. Process for preparation of rosuvastatin calcium
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
EP1601658A1 (en) 2003-11-24 2005-12-07 Teva Pharmaceutical Industries Limited Crystalline ammonium salts of rosuvastatin
US7244844B2 (en) 2003-12-02 2007-07-17 Teva Pharmaceutical Industries Ltd. Reference standard for characterization of rosuvastatin
WO2006017357A1 (en) 2004-07-13 2006-02-16 Teva Pharmaceutical Industries Ltd. A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step
KR101020024B1 (ko) 2005-02-22 2011-03-09 테바 파마슈티컬 인더스트리즈 리미티드 로수바스타틴 알킬에테르를 함유하지 않는 로수바스타틴 및이의 염 및 이의 제조 방법
WO2007022488A2 (en) 2005-08-16 2007-02-22 Teva Pharmaceutical Industries Ltd. Crystalline rosuvastatin intermediate
WO2012073256A1 (en) 2010-11-29 2012-06-07 Cadila Healthcare Limited Salts of rosuvastatin

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US7189703B2 (en) * 1998-01-09 2007-03-13 Intracell, Llc Treatment and diagnosis of alzheimer's disease
AR022462A1 (es) * 1999-02-06 2002-09-04 Astrazeneca Uk Ltd Uso de un agente que disminuye el colesterol
US20030100493A1 (en) * 2001-07-19 2003-05-29 Sol Weiss Sublingual use of inhibitors in the biosynthesis of cholesterol

Similar Documents

Publication Publication Date Title
ME02688B (me) Hinazolinoni kao inhibitori humane fosfatidilinozitol 3 - kinaze delta
IL190150A0 (en) New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimer's disease
JP2005500357A5 (https=)
EA200301165A1 (ru) Лекарственное средство на основе оксикодона
ATE339954T1 (de) Kombinationen von formoterol und tiotropium-salz
IL205262A (en) Use of Risderdone Acid or its Pharmaceutical Salt to produce oral medication once a month for the prevention and treatment of osteoporosis
FI3457135T3 (fi) Fabryn taudin hoitovaihtoehtoja
NO2014032I2 (no) Kombinasjon av rilpivirin eller et farmasøytisk akseptabelt salt av rilpivirin, medregnet hydrokloridsaltet av rilpivirin, emtricitabin og tenofovir, spesielt tenofovir disoproksil eller tenofovirdisoproksilfumarat.
BR0015908A (pt) Emprego de compostos org nicos no tratamento de doenças
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
DK0503440T3 (da) Sumatriptanholdige lægemidler
AU2003259381A1 (en) Use of apoptosis inducing agents in the preparation of a medicament for the treatment of liver diseases
NO20065904L (no) Terapeutiske forbindelser
EP1558214A4 (en) MICROEMULSION CONCENTRATES FOR THE ORAL ADMINISTRATION OF WATER-INSOLICED MEDICAMENT AGAINST COLLECTIONS AND METHOD OF PREPARATION THEREOF
EP1574215A4 (en) SOLID ARZNEI FOR ORAL ADMINISTRATION
JP2006514116A5 (https=)
DE50005529D1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
DK1383752T3 (da) Deutererede 3-piperidinopropiophenoner samt lægemidler indeholdende disse forbindelser
JP2005511619A5 (https=)
TW200624431A (en) Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
RU2004135563A (ru) Лекарственное средство для лечения повышенной активности мочевого пузыря
JP2003526626A5 (https=)
JP2008513510A5 (https=)
JP2005508963A5 (https=)
JP2005505605A5 (https=)